MYCN and childhood malignant neoplasm: Our study agrees that translation has therapeutic vulnerabilities that can be targeted to inhibit MYCN‐dependent tumor growth and provides a potential anticancer strategy using this FDA‐approved drug as an alternative to a small molecule translation inhibitor for treating MYCN‐amplified pediatric cancers.